317318-84-6

Usage

Uses

Used in Athletic Performance Enhancement:
GW0742 is used as a performance-enhancing substance for athletes to improve their stamina. Its fat-affecting properties make it an effective promoter of energy in the body, which can be beneficial for athletes seeking to optimize their physical performance.
Used in Energy Metabolism Promotion:
GW0742 is used as an energy metabolism promoter, helping to increase the oxidative abilities of body muscles. This can lead to improved endurance and overall physical performance.
Used in Pharmaceutical Research:
GW0742 is used as a research compound in the development of drugs targeting PPAR δ receptors. Its selectivity and agonist properties make it a valuable tool for studying the effects of PPAR δ activation on various physiological processes and potential therapeutic applications.

Biological Activity

Potent and highly selective PPAR δ agonist. EC 50 values are 0.001, 1.1 and 2 μ M for transactivation of human PPAR δ , - α , and - γ receptors respectively. Neuroprotective in rat cerebellar granule neuronal cultures after brief (12-hour) exposure but exhibits inherent toxicity after prolonged (48-hour) incubation. Increases rate of fatty acid oxidation and protects against ischemia/reperfusion injury in neonatal and adult cardiomyocytes.

InChI:InChI=1/C21H17F4NO3S2/c1-11-7-14(4-6-17(11)29-9-19(27)28)30-10-18-12(2)26-20(31-18)13-3-5-15(16(22)8-13)21(23,24)25/h3-8H,9-10H2,1-2H3,(H,27,28)

Upstream product

• 22900-83-0 ethyl 2-bromo-4-methyl-1,3-thiazole-5-carboxylate 
• 933782-03-7 (2-bromo-4-methylthiazol-5-yl)methanol 
• 317319-21-4 ethyl 4-methyl-2-[3-fluoro-4-(trifluoromethyl)phenyl]thiazole-5-carboxylate 
• 583883-85-6 (4-dimethylcarbamoylsulfanyl-2-methyl-phenoxy)-acetic acid methyl ester 
• 583883-84-5 (4-dimethylthiocarbamoyloxy-2-methyl-phenoxy)-acetic acid methyl ester 
• 317319-16-7 3-fluoro-4-(trifluoromethyl)thiobenzamide 
• 317319-09-8 (4-acetoxy-2-methylphenoxy)acetic acid methyl ester 
• 166953-80-6 (4-acetyl-2-methylphenoxy)acetic acid methyl ester 
• 317319-10-1 methyl (4-hydroxy-2-methylphenoxy)acetate 
• 56077-47-5 (4-mercapto-2-methyl-phenoxy)-acetic acid methyl ester 
• 876-02-8 4-hydroxy-3-methylphenyl methyl ketone 

Relevant academic research and scientific papers

Parallel Chemistry Approach to Identify Novel Nuclear Receptor Ligands Based on the GW0742 Scaffold

We describe the parallel synthesis of novel analogs of GW0742, a peroxisome proliferator-activated receptor δ (PPARδ) agonist. For that purpose, modified reaction conditions were applied, such as a solid-phase palladium-catalyzed Suzuki coupling. In addition, tetrazole-based compounds were generated as a bioisostere for carboxylic acid-containing ligand GW0742. The new compounds were investigated for their ability to activate PPARδ mediated transcription and their cross-reactivity with the vitamin D receptor (VDR), another member of the nuclear receptor superfamily. We identified many potent PPARδ agonists that were less toxic than GW0742, where ～65 of the compounds synthesized exhibited partial PPARδ activity (23-98%) with EC50 values ranging from 0.007-18.2 μM. Some ligands, such as compound 32, were more potent inhibitors of VDR-mediated transcription with significantly reduced PPARδ activity than GW0742, however, none of the ligands were completely selective for VDR inhibition over PPARδ activation of transcription.

Medicaments

Methods or prevention or treatment of diseases or conditions where inhibition of NO synthase and/or TNF is desirable, the use of PPAR delta activators in such methods and methods for the identification of compounds useful in such treatment.

Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ) - Synthesis and biological activity

We report the synthesis and biological activity of a new series of small molecule agonists of the human Peroxisome Proliferator-Activated Receptor δ (PPARδ). Several hits were identified from our original libraries containing lipophilic carboxylic acids. Optimization of these hits by structure-guided design led to 7k (GW501516) and 7l (GW0742), which shows an EC50 of 1.1 nM against PPARδ with 1000-fold selectivity over the other human subtypes.

Activator of PPAR delta

Compounds of Formula (I) are disclosed. These compounds include selective activators of human PPAR delta.